Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Trogarzonon Mar 09, 2023 7:37pm
109 Views
Post# 35329506

RE:RE:Careers Section

RE:RE:Careers SectionDellusional CEO from Big Pharma that has'nt acheive any deal, acquisition or partnership in the past 3 years.  He's the only one making money at 2M a year and has demolished the company's value with the pipe dreams of Oncology and Nash taht we'rent even his projects to start with.  Has'nt brought any new projects onboeard.  The managed to acut the market cap in half by announcing a pause when they did'nt even have to since it was not requested by the FDA and presented the PR in a completely autodestructive way.  They don't even agnoledge their mistakes.  This CEO is a desaster on the same level as the previous guy John Huss was in his days.  Just did'nt get to do as much damage than this guy in quest of a big win that did'nt pay out on the back of long time shareholders like myself that left their retirement money down the drain.
<< Previous
Bullboard Posts
Next >>